Spi-1 transcriptional activation and wild-type p53 extinction are two oncogenic alterations involved in the malignant transformation of erythroblasts during the Friend acute erythroleukemia. To dissect the contribution of these alterations in the deregulation of the dierentiation and proliferation of erythroblasts, we generated spi-1 transgenic mice. Analysis of these animals revealed that Spi-1 overexpression was directly involved in the block of proerythroblast dierentiation. However, the erythroleukemia that develops in these animals evolved in two steps. During the early step (HS1 step), non tumorigenic proerythroblasts remained strictly dependent upon erythropoietin (Epo) for their survival and proliferation. Later on, Epo-independent and tumorigenic proerythroblasts emerged (HS2 step) suggesting that other oncogenes cooperate with Spi-1 to lead to a fully malignant phenotype. By provirus tagging, we demonstrate that the HS1 step was clonal indicating that a cell selection must occur in vivo. Analysis of the nature of p53 in both the in vivo HS1 and HS2 proerythroblasts and in cultured erythroblastic cell lines showed that ± p53 was normal in the HS1 primary tissues but was mutated in the HS1 cultured cell lines ± p53 was frequently altered in HS2 primary tissues but was found normal in some mice. These data indicate that (i) the blockage of the erythroblast dierentiation by Spi-1 occurs independently of p53 alteration (ii) p53 alteration is not necessary to confer Epo independence and tumorigenicity to spi-1 transgenic proerythroblasts.
Introduction
The murine Friend acute erythroleukemia is a multistage neoplasm induced by the replication-defective retrovirus SFFV (Spleen Focus Forming Virus) (BenDavid and Bernstein, 1991 ) . The early stage of the disease is associated with a polyclonal expansion of proerythroblasts that terminally dierentiate into mature erythrocytes without erythropoietin (Epo). The autonomous proliferation and dierentiation of proerythroblasts is caused by a direct interaction between the gp55 glycoprotein encoded by the SFFV env gene and the Epo receptor which becomes constitutively activated (Aizawa et al., 1990; Li et al., 1990; Longmore and Lodish, 1991) . The late stage of the disease is characterized by the emergence of a clonal population of malignant tumorigenic proerythroblasts arrested in their dierentiation process (Mager et al., 1981; Wendling et al., 1981) . Extensive studies on the genetic alterations involved in the progression of SFFV-infected proerythroblasts towards malignancy have identi®ed two cellular genes spi-1 and p53, mutated in the Friend tumor cells. Due to SFFV insertional mutagenesis, the spi-1 gene is transcriptionally activated resulting in the ectopic expression of Spi-1 protein in proerythroblastic cells (Moreau-Gachelin et al., 1988 Paul et al., 1989) . Mutations of the tumor suppressor gene p53 lead to the loss of normal p53 (Ben-David et al., 1988; Mowat et al., 1985; Munroe et al., 1988) . The apparent contribution of these three biochemical mechanisms to proerythroblast malignant transformation has been recently ascertained in an heterologous system which uses avian primary transgenic erythroblasts expressing a thermosensitive version of the tyrosine protein kinase ts-Sea (Tran Quang et al., 1997) .
During the past years, a persistent question was to clarify the respective role of spi-1 and p53 in proerythroblast immortalization. Their concomitant alterations during the late stage of the Friend disease as well as the accelerated erythroleukemia developed by mice transgenic for a mutated form of p53 and infected with SFFV (Lavigueur and Bernstein, 1991) were evocative of an oncogenic cooperation between these two proteins for the progression of proerythroblasts towards malignancy.
Spi-1/PU.1 is an Ets protein that binds DNA (Klemsz et al., 1990) and RNA (Hallier et al., 1998) . Spi-1/PU.1 plays an essential role in normal lymphopoiesis and myelopoiesis. It regulates the transcription of many myeloid and B lymphoid genes (for review Moreau-Gachelin, 1994) and its inactivation in mice results in a multilineage defect characterized by an absence of B lymphocytes and macrophages (McKercher et al., 1996; Scott et al., 1997) . Although the down regulation of spi-1 during the chemicallyinduced dierentiation of Friend cells suggested that Spi-1 was involved in the dierentiation arrest of the proerythroblast (Schuetze et al., 1992) , the role of Spi-1/PU 1 in the transformation of erythroid cells was deduced from the pathology observed in mice overexpressing a spi-1 transgene (Moreau-Gachelin et al., 1996) . These Spi-1 transgenic mice develop a two step erythroleukemic process. The ®rst step is characterized by a strictly Epo-dependent proliferation of proerythroblastic cells arrested at the stage of differentiation. Later on, an uncontrolled proliferation of proerythroblasts which were Epo-independent and tumorigenic in vivo happens. These data reveal that Spi-1 induces an erythroid dierentiation arrest at the proerythroblast level and that another(other) genetic event(s) must occur to confer full malignancy to the proerythroblast.
p53 is a transcriptional regulator that mediates cell cycle arrest and commitment to apoptosis (Gottlieb and Oren, 1996) . The frequent lesions of the p53 gene in a wide range of human cancers (Greenblatt et al., 1994) , as well as the predisposition of individuals bearing germinal p53 mutation to develop malignancies (Malkin et al., 1990; Srivastava et al., 1990) , suggest that the loss of a normal p53 activity contributes to tumorigenesis. In Friend tumor cells, p53 allelic deletions or missense mutations suggest an incidence of wild-type p53 extinction in the immortalization of erythroid progenitor cells. This is in agreement with the G1 arrest, hemoglobin production and ®nal apoptosis observed in Friend tumor cells expressing a normal exogenous p53 protein (Johnson et al., 1993) .
The multistep erythroleukemia developing in spi-1 transgenic mice appears as an interesting experimental model to assess which oncogenes cooperate with Spi-1 to convert Epo-dependent erythroblasts to full autonomy and tumorigenicity. A ®rst intriguing point was the latency (around 3 months) required for the appearance of the early symptoms. Such a delay is evocative of a selection procedure that may condition the ampli®cation of the spi-1 transgenic proerythroblasts. We reasoned that infection of spi-1 transgenic mice with a replication-competent murine retrovirus that integrates at random in the host cell genome would be a way to tag the transgenic erythroblasts. We show that erythroblasts that invaded the spleen and liver of the transgenic mice are of clonal origin. Given the alterations of p53 during the tumorigenic phase of the Friend erythroleukemia, we analysed the nature of p53 in the dierent steps of the Spi-1-induced erythroleukemic process. We demonstrate that (i) loss of normal p53 expression was not involved in the primary clonal selection and (ii) mutations in the p53 gene did not appear as necessary genetic alterations that collaborated with Spi-1 to induce transgenic proerythroblasts towards a highly malignant status.
Results
Clonal origin of the erythroleukemic disease in spi-1 transgenic mice
The observation that spi-1 transgenic mice develop a disease within a mean latency period of 3.5 months suggested that the proerythroblast population could derive from the clonal expansion of one or a few cells. To examine this question, spi-1 transgenic mice were infected at birth with a replication-competent ecotropic retrovirus F-MuLV (Friend Murine Leukemia Virus). Since retroviruses integrate randomly into the host genome, their integration sites may be used as markers of clonality. To avoid an overlap between the pathology developed by the transgenic mice and the hematopoietic malignancies caused by F-MuLV (Wendling et al., 1983) , the B3 strain was chosen. It was previously reported that B3 had a low virulence and induced various types of leukemias only after more than 10 months (Sitbon et al., 1986) . Among the 58 B3-infected spi-1 transgenic mice, 28 developed the hepatosplenomegaly (HS1) and anemia characteristics of the transgenic disease (Moreau-Gachelin et al., 1996) . The incidence of the disease (48%) was similar to that observed in uninfected transgenic mice, whereas the mean latency of outgrowth (3.0+1.5 months) appeared slightly shorter than in uninfected animals (3.6+1.5 months). B3-infected transgenic mice which did not develop the transgenic disease, exhibited after 10 ± 16 months the expected pattern of various leukemias as observed in non transgenic virus-infected animals (data not shown).
Gross examination at autopsy, blood parameters and¯ow cytometry analyses were unable to distinguish diseased non-infected transgenic mice from infected ones (data not shown). Upon in vitro cultures, B3-infected transgenic spleen and bone marrow cells from diseased mice established as permanent proerythroblastic cell lines blocked in their dierentiation and strictly dependent upon Epo for their proliferation. Both cells in vivo and in culture overexpressed the transgene (data not shown). Collectively, these results demonstrate that B3 infection of transgenic mice did not interfere with the pathology induced by the overexpression of the transgene.
High molecular weight DNAs isolated from spleen and liver from six diseased B3-infected transgenic mice (R70, R73, R78, R81, R83, R87) were cleaved with either HindIII or EcoRI which produce a single proviral-cell DNA junction fragment. Southern blot hybridized with a F-MuLV env probe ( Figure 1c ) revealed one or a few discrete bands corresponding to the B3 integration sites in all tissues tested (Figure 1a ), indicating that the proerythroblast population in spi-1 transgenic mice derives from a single or a few cells in which a selection procedure must have occurred.
We have previously shown that, when spi-1 transgenic mice were repeatedly transfused with red blood cells, the hepatosplenomegaly (HS1) regressed but always relapsed after around 20 days (HS2). In the HS2 step, proerythroblast proliferation was growth factor-independent and these cells were also tumorigenic in vivo (Moreau-Gachelin et al., 1996) . F-MuLV (B3) infection did not change the timing of the disease progression or the properties of the proliferating proerythroblasts which were Epo-independent in vitro and tumorigenic in vivo. By Southern blotting, proviral integration sites were also detected as discrete bands in the HS2 tissues ( Figure 1b ). To determine whether proerythroblasts in the HS2 phase were derived from the HS1 population, we used the following approach. Spi-1 transgenic mice were infected at birth with FMuLV (B3). When a spleen enlargement was detected by palpation in an animal, a splenectomy was performed. Subsequently, animals were transfused with red blood cells twice a week and checked every week until a relapse was apparent. Four animals (R71, R77, R79, R82) survived such a surgery, diseased leukemic mice had elevated numbers of blasts in their peripheral blood and either in®ltrated mesenteric lymph nodes (R71, R82), hepatomegaly (R77 and R79) or extramedullary hematopoiesis seen in the ovaries (R82). DNAs from in®ltrated tissues taken during the HS1 and HS2 phases were HindIII-digested and analysed by Southern blotting. Identical bands were observed in DNA from HS1 and HS2 tissues isolated from the same animal ( Figure 1b ). These data demonstrate that HS2 proerythroblasts derived from the HS1 population and allow the conclusion that the whole erythroleukemic process is clonal in these transgenic mice.
Expression of p53 in transgenic tissues and cell lines
As p53 alterations may represent one of the genetic lesions possibly involved in the progression of the erythroleukemic process, we checked for abnormalities of the p53 gene both in primary tissues taken during the HS1 and HS2 phases of the disease and in cultured cell lines derived from these tissues. Transcription of p53 was analysed in the enlarged spleens of four mice (R33, R63, R83 and R89) during the HS1 phase and in the cell lines derived from either the spleen or the bone marrow of these diseased mice. On Nothern blots (Figure 2) , the expected 2.5 kb p53 messenger RNA was detected in all tissues and cell lines. p53 expression was also analysed in the spleen of six mice during the late hepatosplenomegaly (HS2). Four of them (R21, R22, R31, R49) exhibited a normal p53 expression pattern, whereas no p53 transcript could be detected in the spleen of mice R10 and R60. No p53 allelic deletion in the genome of R10 and R60 mice that could account for p53 extinction was observed on Southern blots (Figure 3a) .
To further assess whether the expressed p53 transcripts were normal, their coding region was ampli®ed by RT ± PCR and the nucleotide sequence was determined. All p53 RNAs ampli®ed from tissues (bone marrow, spleen or liver) taken from mice (R33, R63, R83 and R89) during the HS1 phase were wildtype. In contrast, mutations were detected in the p53 transcripts from each cell line established from R33, R83 and R89 tissues (Table 1) . In both the cell lines derived from the spleen and the bone marrow of mouse R89, a deletion of the nucleotide 505 introduced a frameshift in the p53 transcript leading to the potential expression of a 242 amino acid truncated protein aberrant in its carboxy terminal region. In both the spleen and bone marrow cell lines established from mouse R33, a transversion of nucleotide 394 (G?C) leads to an amino acid 132 substitution (Ala?Pro). In the R83 spleen cells-derived cell line, a transition of nucleotide 509 (G?A) changes Cys 170 in Tyr. Each one of these mutations are located in the region encoded by the exon 5 of the p53 gene. In all these cell lines, no wild-type p53 sequence was ampli®ed suggesting that the wild-type p53 allele was transcriptionally silent. Thus, these data reveal that no mutation could be detected in the p53 gene expressed in the transgenic tissues of mice during the HS1 step of the disease, whereas mutations were found in the p53 transcripts from the corresponding cultured cell lines. To con®rm that the absence of p53 mutation in primary HS1 tissues was not due to the analysis of p53 transcripts expressed by contaminating non preneoplastic cells, we sequenced the genomic exon 5 from R33, R83 and R89 spleen DNAs corresponding to the region found mutated in cDNAs prepared from the corresponding spleen cell-derived cell lines. No mutations were found strengthening the conclusion that the majority of the HS1 spleen cells carry wild type p53 alleles.
We next investigated the nature of the p53 gene during the HS2 phase of the disease (mice R10, R21, R22, R31, R49, R60 in Table 1 ). In mice R10 and R60, and in repeated assays, no ampli®cation of p53 transcripts could be obtained agreeing with the absence of p53 expression observed on Northern blots (Figure 2) . In mouse R49, nucleotide 839 was mutated (A?G) leading to the substitution of Glu 280 to Gly. Moreover an additional 5 kb HindIII p53 fragment appeared on Southern blot of R49 DNA ( Figure 3b ). As (A?G) mutation does not generate a HindIII restriction endonuclease site, we can conclude that two mutation events occurred on p53 gene in this animal. In mouse R22, a deletion of the entire exon 7 (aa 219 ± 255) leading to the expression of a potentially truncated p30 protein was detected. This deletion appeared as a 2 kb EcoRI fragment on Southern blot of R22 DNA (Figure 3a) . In contrast, wild-type p53 transcripts were found in spleen cells from mice R21 and R31. Thus among the six HS2 spleens analysed, p53 expression was switched o in two, normal in two and the gene was mutated in two.
Discussion
Transgenic mice overexpressing the spi-1 gene in erythroid cells develop an erythroleukemic process that has been instrumental to de®ne the role of Spi-1 in the blockage of proerythroblast dierentiation (Moreau-Gachelin et al., 1996) . In addition the multistep evolution of the disease suggests that activation of another(other) putative oncogene(s) might be necessary for the proerythroblast to reach full malignancy. Such a presumption implies that a cell selection must happen with regard to the occurrence of oncogenic alterations. We investigated whether the transformation of the spi-1 transgenic proerythroblasts was clonal by using an in vivo procedure based upon provirus tagging. Since F-MuLV alone has the capability to generate late occurring hemopoietic neoplasia, we had to consider the possibility that FMuLV could act as an insertional mutagen leading to the activation of an oncogene which could provide a growth advantage to a subpopulation of spi-1 transgenic proerythroblasts. Previous reports have indeed shown that such a strategy allowed the The nucleotide sequence of p53 was determined by RT ± PCR on mRNA from tissues and cell lines and subsequent sequencing of products. Nucleotide sequences were analysed several times as indicated in brackets from independent RT ± PCR reactions. Deleted nucleotides (Dn), mutated amino acids and deleted amino acids (D) are indicated. N: normal, nd: not determined, UA unampli®ed Figure 4 Schematic representation of p53. The transactivator domain (TA), the DNA binding domain (DBD), the dimerization domain (dm) and the tetramerization domain (tm) are shown. Nucleotides and amino acids are numbered according to Soussi and May (1996) . Black boxes indicate the phylogenetically conserved domains where hot spot mutations are clustered. Mutations detected in the p53 tissues or cell lines from spi-1 transgenic mice are positioned. C269 is the punctual mutation detected in the cDNA from 745A cell line identi®cation of oncogenes cooperating with a transgene in other neoplasm systems (Van Lohuizen et al., 1991) . We show that infection of spi-1 transgenic mice at birth with a F-MuLV of low virulence (B3) did not change the physiopathological pattern of the disease. In addition, the progression from HS1 to HS2 was not modi®ed by F-MuLV infection. Together, these data strongly argue against a cellular selection eect due to F-MuLV. Discrete proviral integration sites were detected in genomic DNA prepared from primary HS1 and HS2 tissues. Moreover, the F-MuLV integration sites were identical when the spleen and the liver from the same mouse in the HS1 step were analysed (Figure 1a) . Furthermore, when both HS1 and HS2 proerythroblasts were isolated from one diseased mouse, both presented the same pro®le of integration sites ( Figure  1b) . All together these data revealed that the early step of the transgenic disease was clonal and that HS2 proerythroblasts derived from HS1 proerythroblasts.
The clonal nature of the HS1 erythroblast population was unexpected since transgenic proerythroblasts were presumed to be identical. The event that leads to the clonal ampli®cation of the Epo-dependent erythroblastic population is unknown. Because of the short latency of the outgrowth of the disease (3.5 months) in these transgenic animals, it can be hypothesized that this event is related to the derepression of the transgene expression. Such derepression can occur stochastically in a cell as a consequence of a position-eect variegation (Elliot et al., 1995; Milot et al., 1996) . It can also be determined genetically by activation of regulatory factors that interact with the transcriptional enhancers that drive the transgene transcription. Indeed, our previous observations have shown that the transgene was silent during the embryonic and neonatal life and was not expressed in the transgenic mice that remained healthy (Moreau-Gachelin et al., 1996) . However, the clonality of the disease can also re¯ect a cellular selection process with regard to the occurrence of a biochemical event necessary to the Spi-1 function. Several approaches have shown that constitutive activation of the Epo receptor either by the gp55 encoded by the SFFV env gene in the early phase of the Friend erythroleukemia or by the point mutation (R129C) (Longmore and Lodish, 1991) are sucient to induce hyperplasia of erythroblastic cells. Although in the HS1 step of the erythroleukemia developing in spi-1 transgenic mice, erythroblasts remained totally dependent upon Epo for their survival and proliferation both in vivo and in vitro, we checked whether alterations in the signaling pathway from the Epo receptor could be detected. Stat5 is a transcription factor whose activity is speci®cally induced by Epo in Epo-dependent cell lines (Gobert et al., 1996) . Studies were performed with HS1 Epo-dependent cell lines derived from R33 and R83 spleens. No constitutive activation of Stat 5 was detected following cytokine deprivation, whereas normal Stat5 activation could be observed after Epo stimulation (data not shown). These data indicate that the activation of the Epo receptor leads to a normal signal transduction in these cells.
According to the apparent participation of p53 mutations in the Friend erythroleukemic process, we looked for p53 gene alterations by analysing both the expression level and the nature of the p53 transcripts in HS1 and HS2 tissues and cell lines (Figure 2) . We observed that, in HS1 tissues, p53 RNAs were wildtype and expressed at a normal level. In contrast, mutations were detected in all cell lines derived from these tissues. Notably, when cell lines were derived from two dierent tissues from the same mouse (spleen and bone marrow from mouse R33, R83 or R89), the same mutation was detected. This result strongly suggests that mutation of p53 was not related to the cell culture but was already present in vivo. As no p53 mutation could be detected both in DNA and RNA of the HS1 erythroblasts from spleens, we deduced that these mutations were present in minor cell populations which were selected and ampli®ed by the culture procedure. Thus the expression of wild-type p53 in HS1 spleen cells demonstrates that p53 alteration does not cooperate with Spi-1 to block the erythroid dierentiation. In contrast, alteration of p53 appears as a frequent molecular event involved in tumor progression since p53 mutations or inactivation were detected in four of six HS2 spleens.
The p53 protein is a transcription factor which contains an amino-terminus transactivator domain, a central DNA binding domain and a carboxy-terminus oligomerization domain (for review; Levine, 1997) . Five amino acids clusters, one in the transactivator domain and four in the DNA binding domain are highly conserved between diverse species (Figure 4) . In human cancers, the most frequent mechanism which inactivates the wild-type p53 is point mutations that occur in`hot spots' located inside the evolutionary conserved regions (Soussi and May, 1996) . Ninety per cent of the mutations reside in the DNA binding domain between amino acids residues 102 and 292 and result in the loss of the p53 ability to act as a transcriptional regulator (for review, Cho et al., 1994; Prives, 1994) .
In murine neoplasms, the frequency of p53 mutations is poorly known. Most murine leukemias are induced by retroviruses such as Abelson MuLV, Friend MuLV and SFFV and cell selection with regard to the p53 inactivation occurs mainly by molecular mechanisms related to the retroviral replication cycle (Ben-David et al., 1988; Hicks and Mowat, 1988; Wol and Ruscetti, 1985) . In Friend tumor cell lines, 3 cases of p53 missense mutations at positions 187 (His?Arg), 190 (Arg?Pro) and 233 (Asn?Asp) have been reported (Munroe et al., 1990) and, during this study, we have detected a mutation at position 269 (Cys?Ser) in the 745A cell line. In the spi-1 transgenic mouse model, p53 expression is changed in a variety of ways that lead to either p53 extinction or expression of a putative protein mutated in its DNA binding domain. In one HS1 cell line, a nonsense mutation generated a truncated protein devoid of the two last evolutionary conserved domain and the oligomerization domain. In other HS1 cell lines and in HS2 tissues, mutations ocurred in the II-V conserved regions of the DNA binding domain and fell in the`hotspot' domains described in human malignancies. Interestingly the expression from the normal allele was lost in any of the cells where a mutated p53 was expressed. Moreover a dominant function of mutant p53 cannot be argued as a cooperating event in the transformation of proerythroblastic cells since in two HS2 cases, p53 transcription was knocked out. p53 alterations were not detected in the HS1 erythroblasts in vivo. Thus we can conclude that p53 alteration does not cooperate with Spi-1 overexpression in the blockage of erythroid dierentiation during the primary step of the spi-1 transgenic disease. p53 mutation was only detected in vitro in the HS1 erythroblastic cell subpopulation that could be established as permanent cell lines. Nevertheless, these cell lines remained strictly dependent on Epo for their survival and proliferation and they did not induce tumors in nude mice. Furthermore, during the later phase of the erythroleukemia, HS2 proerythroblasts from two of the six animals examined, expressed a wild-type p53. All together these data suggest that p53 mutation is neither necessary nor sucient to induce growth factor independence and malignancy in the proerythroblast. However analysis of the disease developed in double mutant p53 null/spi-1 transgenic mice are currently in progress to clarify more directly the role of p53 in the evolution of this erythroleukemic process.
Materials and methods

Viral infection and splenectomy
Spi-1 transgenic newborn mice (less than 24 h old) were intraperitoneally injected with 100 ml of supernatant from NIH3T3-F-MuLV (B3) producing cells. Virus titer, estimated by plating culture supernatants on S + L 7 mouse cells (Bassin et al., 1971) was 1610 6 focus forming virus. Mice were checked by palpation every week as previously described (Moreau-Gachelin et al., 1996) . Splenectomy was performed under profound anesthesia provided with an intraperitoneal injection of 0.1 ml/mouse of a mixture containing 15% of Ketalar and 27.5% of Rompun in physiological solution.
Southern blot analysis
High molecular weight DNAs were prepared as previously described (Moreau-Gachelin et al., 1985) . Ten mg of DNAs were digested with HindIII or EcoRI restriction endonucleases, subjected to electrophoresis on 0.8% agarose gel, transferred to nitrocellulose ®lter, hybridized with probes 32 P-labeled by random priming using a multiprime labeling kit (Amersham, France), washed and autoradiographed as reported elsewhere (Moreau-Gachelin et al., 1985) . The murine p53 cDNA probe was a BglII ± BamHI fragment of p53 cDNA from the pSVp53C17 plasmid (Eliyahu et al., 1988) . The ectopic virus env probe was a 350 bp BamHI ± SmaI fragment from the env region of the F-MuLV cloned in E57BS1 plasmid (Moreau-Gachelin et al., 1983) .
Northern blot analysis
Total cellular RNAs were prepared by guanidium isothiocyanate extraction (Chomczynski and Sacchi, 1987) from tissues and cell lines. Twenty mg of total RNAs were subjected to electrophoresis on a denaturing 1% agarose gel, transferred to gene screen ®lter, hybridized with cDNA probes labeled with 32 P-dCTP in a random priming reaction and washed as previously described (MoreauGachelin et al., 1986) . Standardization of RNA loading was controled by hybridization of the blots with a GAPDH probe: a PstI fragment of rat GAPDH cDNA (Fort et al., 1985) .
cDNA synthesis and ampli®cation cDNA were synthesized with SuperScript II reverse transcriptase (Gibco ± BRL) in the presence of 5 mg of total RNAs, 0.5 mM each dATP, dCTP, dGTP and dTTP, 0.1 mM of the p53 speci®c primer RT3' (5'-AAGTCATAA-GACAGCAAGGAGA-3'), 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl 2 , 10 mM dTT, 200 U of SuperScript II reverse transcriptase in a ®nal volume of 20 ml and incubated for 50 min at 428C. Two ml of the reverse transcription reaction were used as the PCR template in a reaction mixture containing 2.5 mM of the p53 speci®c primers, 75 mM Tris-HCl pH 9.0, 20 mM (NH 4 ) 2 SO 4 , 0.5 mM MgCl 2 , 0.25 mM each dATP, dCTP, dGTP, dTTP and 2.5 U of Goldstar DNA polymerase (Eurogentec) in a ®nal volume of 40 ml. The cDNAs were ampli®ed for 40 cycles under the following conditions: denaturation (928C, 30 s), annealing (598C 1 min 30 s), elongation (728C, 2 min) with a ®nal elongation at 728C for 7 min. The following p53 speci®c primers were used for amplifying the complete coding region: ATG (5'-TGTCACGCTTCTCCG-AAGACT-3'), 283 (5'-CCTTCTAAAAAACTTACCA-3'), 327 (5'-TTCCTGCAGTCTGGGACAGC-3'), 583 (5'-GA-AGGAAATTTGTATCCCGA-3'), 625R (5'-AAAGTCT-GCCTGTCTTCCAG-3'), 891R (5'-GGCAGTTCAGGG-CAAAGGAC-3'), STOP (5'-TGATGGGGACGGATGCA-GA-3').
Direct DNA sequencing of PCR products
The PCR products were puri®ed from agarose gel by the geneclean II kit (BIO 101, Inc.). One hundred ng of PCR products were subjected to a sequencing reaction using the ThermoSequenase cycle sequencing kit (Amersham) in the presence of a 5' end g 33 P-dATP (NEN) labeled primer (the same as in PCR reactions). Sequence analysis were done several times (as indicated in Table 1 ) from dierent p53 RT ± PCR ampli®ed RNA for each tissue or cell line. p53 genomic DNA ampli®cation 0.5 mg of genomic DNA was subjected to a PCR reaction in the conditions used for cDNA ampli®cation. The exon 5 of the murine p53 gene was ampli®ed with the speci®c primers: int-4 (5'-TCTCTCCTCTCTTCCAGTAC-3'), int-5 (5'-CTTACCATCACCATCGGAGC-3').
